815 material Form 8-K filings that 659 companies we cover made with the SEC in March 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Marker Therapeutics reported results for the year ended December 31, 2025, with grant income of $3.5 million, down from $6.6 million in 2024, and a net loss of $12.2 million, up from $10.7 million. The company said its existing cash and cash equivalents will fund operating expenses through the fourth quarter of 2026, assuming no additional grant funds are received.
Grant income was $3.5 million for 2025, versus $6.6 million for 2024.
Net loss was $12.2 million, or $0.79 per share, versus $10.7 million, or $1.19 per share, in 2024.
Research and development expenses were $11.8 million, versus $13.5 million in 2024; general and administrative expenses were $4.2 million, flat year over year.
Cash, cash equivalents and restricted cash were $17 million at December 31, 2025, which the company expects to fund operations through the fourth quarter of 2026.
Five Below reported fourth-quarter fiscal 2025 net sales up 24.3% to $1.73 billion, with diluted EPS of $4.28 versus $3.39 a year earlier. For the full year, net sales rose 22.9% to $4.76 billion and diluted EPS rose to $6.47 from $4.60, and the company issued fiscal 2026 guidance calling for diluted EPS of $7.69 to $8.20.
Q4 net sales $1.73 billion, up from $1.39 billion; comparable sales up 15.4%
Q4 diluted EPS $4.28 vs $3.39; adjusted diluted EPS $4.31 vs $3.48
Fiscal 2026 outlook: net sales $5.20 billion to $5.30 billion; diluted EPS $7.69 to $8.20
Q1 fiscal 2026 outlook: net sales $1.18 billion to $1.20 billion; diluted EPS $1.55 to $1.67
Micron reported fiscal second-quarter 2026 revenue of $23.86 billion for the quarter ended February 26, 2026, up from $13.64 billion in the prior quarter and $8.05 billion a year earlier. GAAP diluted earnings per share were $12.07, compared with $4.60 in the prior quarter, and the company guided third-quarter revenue to $33.5 billion plus or minus $750 million. The board also approved a 30% increase in the quarterly dividend to $0.15 per share.
Revenue was $23.86 billion, versus $13.64 billion in fiscal Q1 2026 and $8.05 billion in fiscal Q2 2025.
GAAP net income was $13.79 billion, or $12.07 per diluted share; non-GAAP diluted EPS was $12.20.
Third-quarter 2026 guidance: revenue of $33.5 billion plus or minus $750 million, and GAAP diluted EPS of $18.90 plus or minus $0.40.
Quarterly dividend of $0.15 per share is payable April 15, 2026, to holders of record as of March 30, 2026.
Progressive reported February 2026 results in a news release furnished under Item 7.01, covering the month ended February 28, 2026. Net income rose 2% to $943 million and earnings per share rose 2% to $1.61, while net premiums written grew 5% to $6,995 million, but the combined ratio worsened to 85.7 from 82.6 a year earlier. The filing contains no guidance changes.
February net income $943 million vs. $928 million a year earlier (up 2%)
Diluted EPS $1.61 vs. $1.58 (up 2%); combined ratio 85.7 vs. 82.6 (3.1 points higher)
Management said February premium growth is about 2-3 points lower due to a month-end closing timing nuance; March results are due April 15, 2026
Williams-Sonoma reported fourth quarter fiscal 2025 net revenues of $2.36 billion, down from $2.46 billion a year earlier, which included a 14-week quarter, while comparable brand revenue rose 3.2% and diluted EPS fell to $3.04 from $3.28. Full-year diluted EPS of $8.84 was a record, and the board raised the quarterly dividend 15% to $0.76 per share, which matters to shareholders because it increases cash returns even as quarterly profit declined.
Q4 operating income was $478 million, with an operating margin of 20.3%, down from 21.5% a year earlier.
Fiscal 2025 diluted EPS was a record $8.84, up 0.6%, on net revenues of $7.81 billion.
Fiscal 2026 outlook calls for net revenue growth of 2.7% to 6.7% and an operating margin of 17.5% to 18.1%, including tariff effects front-loaded in the first half.
Quarterly dividend rises to $0.76 per share, payable May 22, 2026, to holders of record as of April 17, 2026.
Macy's reported fourth-quarter and fiscal 2025 results on March 18, 2026, with comparable sales up 1.5% for the year but net sales down 2.4% to $21.8 billion. Adjusted diluted EPS fell to $2.32 from $2.64 a year earlier, and 2026 adjusted EPS guidance of $1.90 to $2.10 sits below the $2.15 fiscal 2025 figure shown on the updated basis. GAAP results were boosted by a $328 million interchange fee settlement, and the board raised the quarterly dividend 5%.
Q4 2025 net sales were $7.6 billion, down 1.7%, while comparable sales rose 1.8%; adjusted diluted EPS was $1.67 versus $1.80 a year earlier.
Fiscal 2025 GAAP and adjusted diluted EPS were each $2.32, above the company's $2.00 to $2.20 guidance range, against GAAP EPS of $2.07 and adjusted EPS of $2.64 in fiscal 2024.
Fiscal 2026 guidance calls for net sales of $21.4 billion to $21.65 billion and adjusted diluted EPS of $1.90 to $2.10.
Quarterly dividend raised 5% to 19.15 cents per share, payable April 1, 2026; about $1.1 billion remained under the $2.0 billion buyback authorization at fiscal year-end.
General Mills reported fiscal 2026 third-quarter results on March 18, 2026, with net sales of $4.4 billion, down 8%, and diluted EPS of $0.56, down 50%. The company reaffirmed its full-year fiscal 2026 targets, which include adjusted operating profit and adjusted diluted EPS both expected to be down 16 to 20 percent in constant currency. For shareholders, the quarter shows steep declines in sales and earnings, while the unchanged outlook signals that management still expects a fourth-quarter improvement.
Third-quarter net sales were $4.4 billion, down 8%, with organic net sales down 3%.
Diluted EPS was $0.56, down 50%; adjusted diluted EPS was $0.64, down 37% in constant currency.
Operating profit was $525 million, down 41%; nine-month operating profit rose 6% to $3.0 billion, driven by a $1.0 billion gain on divestitures.
Full-year fiscal 2026 organic net sales are expected to be down 1.5 to 2 percent.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.